35525902|t|Oxime derivative TFOBO promotes cell death by modulating reactive oxygen species and regulating NADPH oxidase activity in myeloid leukemia.
35525902|a|Several derivatives derived from the oxime structure have been reported as potential anticancer agents in various cancers. Here, we first tested a novel oxime-containing derivative of 2-((2,4,5-trifluorobenzyl)oxy)benzaldehyde oxime (TFOBO) to evaluate its anticancer effect in myeloid leukemic cells. Compared to (2-((2,4,5-trifluorobenzyl)oxy)phenyl)methanol (TFOPM), the oxime derivative TFOBO suppresses leukemic cell growth by significantly increasing reactive oxygen species (ROS) levels and cell death. Leukemic cells treated with TFOBO displayed apoptotic cell death, as indicated by nuclear condensation, DNA fragmentation, and annexin V staining. TFOBO increases Bax/Bcl2 levels, caspase9, and caspase3/7 activity and decreases mitochondrial membrane potential. ROS production was reduced by N-acetyl-L-cysteine, a ROS scavenger, diphenyleneiodonium chloride, a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor, after exogenous TFOBO treatment. ROS inhibitors protect leukemic cells from TFOBO-induced cell death. Thus, our study findings suggest that TFOBO promotes apoptosis by modulating ROS and regulating NADPH oxidase activity. Collectively, the oxime-containing derivative TFOBO is a novel therapeutic drug for myeloid leukemia.
35525902	0	5	Oxime	Chemical	MESH:D010091
35525902	17	22	TFOBO	Chemical	-
35525902	57	80	reactive oxygen species	Chemical	MESH:D017382
35525902	96	109	NADPH oxidase	Gene	50506
35525902	122	138	myeloid leukemia	Disease	MESH:D007951
35525902	177	182	oxime	Chemical	MESH:D010091
35525902	254	261	cancers	Disease	MESH:D009369
35525902	293	298	oxime	Chemical	MESH:D010091
35525902	324	372	2-((2,4,5-trifluorobenzyl)oxy)benzaldehyde oxime	Chemical	-
35525902	374	379	TFOBO	Chemical	-
35525902	418	434	myeloid leukemic	Disease	MESH:D007951
35525902	454	500	(2-((2,4,5-trifluorobenzyl)oxy)phenyl)methanol	Chemical	-
35525902	502	507	TFOPM	Chemical	-
35525902	514	519	oxime	Chemical	MESH:D010091
35525902	531	536	TFOBO	Chemical	-
35525902	548	556	leukemic	Disease	MESH:D007938
35525902	597	620	reactive oxygen species	Chemical	MESH:D017382
35525902	622	625	ROS	Chemical	MESH:D017382
35525902	650	658	Leukemic	Disease	MESH:D007938
35525902	678	683	TFOBO	Chemical	-
35525902	777	786	annexin V	Gene	308
35525902	813	816	Bax	Gene	581
35525902	817	821	Bcl2	Gene	596
35525902	830	838	caspase9	Gene	842
35525902	844	854	caspase3/7	Gene	836;840
35525902	912	915	ROS	Chemical	MESH:D017382
35525902	942	961	N-acetyl-L-cysteine	Chemical	MESH:D000111
35525902	965	968	ROS	Chemical	MESH:D017382
35525902	980	1008	diphenyleneiodonium chloride	Chemical	MESH:C007517
35525902	1012	1071	nicotinamide adenine dinucleotide phosphate (NADPH) oxidase	Gene	50506
35525902	1099	1104	TFOBO	Chemical	-
35525902	1116	1119	ROS	Chemical	MESH:D017382
35525902	1139	1147	leukemic	Disease	MESH:D007938
35525902	1262	1265	ROS	Chemical	MESH:D017382
35525902	1281	1294	NADPH oxidase	Gene	50506
35525902	1323	1328	oxime	Chemical	MESH:D010091
35525902	1389	1405	myeloid leukemia	Disease	MESH:D007951
35525902	Negative_Correlation	MESH:D010091	MESH:D007938
35525902	Negative_Correlation	MESH:D010091	MESH:D007951
35525902	Positive_Correlation	MESH:D010091	MESH:D017382
35525902	Negative_Correlation	MESH:D010091	MESH:D009369
35525902	Association	MESH:D007938	308
35525902	Association	MESH:D007951	50506
35525902	Negative_Correlation	MESH:C007517	50506
35525902	Negative_Correlation	MESH:D000111	MESH:D017382
35525902	Association	MESH:D017382	MESH:D007938
35525902	Negative_Correlation	MESH:C007517	MESH:D017382

